RADNOR, Pa., Nov. 20, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").

On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen higher-than-normal levels of cancellations in the third quarter. As a result of the cancellations, Medpace's net book-to-bill ratio, a key indicator of demand, was just 1.00 for the quarter, below analyst estimates and the lowest in Medpace's history as a public company, according to one Truist analyst.

RADNOR, Pa., Nov. 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").

On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen higher-than-normal levels of cancellations in the third quarter. As a result of the cancellations, Medpace's net book-to-bill ratio, a key indicator of demand, was just 1.00 for the quarter, below analyst estimates and the lowest in Medpace's history as a public company, according to one Truist analyst.

NEW YORK, Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

RADNOR, Pa., Nov. 9, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").

On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen higher-than-normal levels of cancellations in the third quarter. As a result of the cancellations, Medpace's net book-to-bill ratio, a key indicator of demand, was just 1.00 for the quarter, below analyst estimates and the lowest in Medpace's history as a public company, according to one Truist analyst.

NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP.

NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Oct. 30, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP.

RADNOR, Pa., Oct. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").

On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen higher-than-normal levels of cancellations in the third quarter. As a result of the cancellations, Medpace's net book-to-bill ratio, a key indicator of demand, was just 1.00 for the quarter, below analyst estimates and the lowest in Medpace's history as a public company, according to one Truist analyst.

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

LOS ANGELES, Oct. 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Medpace reported its third quarter 2024 financial results on October 21, 2024, also cutting its revenue guidance for the full year on the same day. During its investor call held the next day, the Company described a higher level of cancellations in the third quarter. The Company's net book-to-bill ratio was a low 1.00 for the third quarter, below analyst estimates and historically low when compared to its past performance.

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Medpace Holdings, Inc. (NASDAQ: MEDP) ("Medpace").

On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen higher-than-normal levels of cancellations in the third quarter. As a result of the cancellations, Medpace's net book-to-bill ratio, a key indicator of demand, was just 1.00 for the quarter, below analyst estimates and the lowest in Medpace's history as a public company, according to one Truist analyst.

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP.

NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Sept. 29, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP.